TY - JOUR
T1 - Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy
AU - Amagai, Ryo
AU - Fujimura, Taku
AU - Kambayashi, Yumi
AU - Sato, Yota
AU - Tanita, Kayo
AU - Hashimoto, Akira
AU - Aiba, Setsuya
PY - 2019/5
Y1 - 2019/5
N2 - Anti-programmed death 1 antibody monotherapy is a first-line and widely used immunotherapy for the treatment of advanced melanoma. However, its efficacy rate is lower in the Japanese population compared with the Caucasian population. Ipilimumab is another immune checkpoint inhibitor (ICI) that activates and increases T cells, which suppress the function of regulatory T cells. Previous reports have suggested that ipilimumab is useful for treating advanced melanoma, particularly in combination with radiation therapy. In this report, we described three cases of nivolumab-resistant melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy, which may enhance the therapeutic effects of the sequential administration of ICI.
AB - Anti-programmed death 1 antibody monotherapy is a first-line and widely used immunotherapy for the treatment of advanced melanoma. However, its efficacy rate is lower in the Japanese population compared with the Caucasian population. Ipilimumab is another immune checkpoint inhibitor (ICI) that activates and increases T cells, which suppress the function of regulatory T cells. Previous reports have suggested that ipilimumab is useful for treating advanced melanoma, particularly in combination with radiation therapy. In this report, we described three cases of nivolumab-resistant melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy, which may enhance the therapeutic effects of the sequential administration of ICI.
KW - adverse events
KW - intensity-modulated radiotherapy
KW - ipilimumab
KW - low-dose radiation therapy
KW - nivolumab
UR - http://www.scopus.com/inward/record.url?scp=85063317347&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063317347&partnerID=8YFLogxK
U2 - 10.1111/1346-8138.14861
DO - 10.1111/1346-8138.14861
M3 - Article
C2 - 30908705
AN - SCOPUS:85063317347
VL - 46
SP - 449
EP - 452
JO - Journal of Dermatology
JF - Journal of Dermatology
SN - 0385-2407
IS - 5
ER -